Illumina beat analysts' expectations and its earnings target for the first quarter, and raised guidance for the rest of the year.
Affymetrix and Illumina settled their lawsuit for a one-time payment by Illumina of $90 million, terms that were highly favorable for Illumina.
Illumina was sued by Affymetrix, its primary competitor, for copyright infringement with regard to its DNA microarray technologies. A ruling is still pending.